Pulmonary Disease is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Ventolin HFA (Albuterol) is an Inhaled beta-2-agonist. Studies have shown the use of Ventolin (Albuterol) had an improvement in Pulmonary disease compared to the baseline. Other studies have shown the use of Ventolin (Albuterol) is safe for patients older than 4. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of Ventolin (Albuterol) within 7 days of hospitalization was associated with lower hospital readmission rates for Pulmonary Disease Patients. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

Chronic Obstructive Pulmonary Disease (COPD) is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. PROAIR(Albuterol) Inhaled beta-2-agonist. Studies have shown that PROAIR(Albuterol) delivers a warmer, lower-impact, and longer-lasting plume compared to its competitors. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of PROAIR(Albuterol)within 7 days of hospitalization was associated with lower hospital readmission rates for Chronic Obstructive Pulmonary Disease (COPD) Patients. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

Atrial fibrillation (AFib) is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. XARELTO (Rivaroxaban) is a Factor XA inhibitor that helps reduce the risk of blood clots in conditions like atrial fibrillation (AFib), deep vein thrombosis (DVT), and pulmonary embolism (PE) . Studies have shown that the use of XARELTO (Rivaroxaban) was associated with shorter Length of Stay (LOS) and decreased costs for patients with Low-Risk Pulmonary Embolism (PE). Two studies have confirmed XARELTO’s (rivaroxaban) positive benefit-risk profile in treating venous thromboembolism (VTE), reducing blood clots, and reducing the risk of recurrence. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of XARELTO (Rivaroxaban) within 7 days of hospitalization was associated with lower hospital readmission rates for atrial fibrillation (AFib). Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

Pulmonary Disease is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Symbicort/ Budesonide / Formoterol is an inhaled glucocorticoid and long acting beta-2-agonist. Studies have shown that the use of Symbicort/ Budesonide / Formoterol minimizes the risk of readmission compared to other treatments for Pulmonary disease. Other studies have shown the use of Symbicort/ Budesonide / Formoterol reduces the annual rate and severity of exacerbations caused by Pulmonary Disease. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of Symbicort/ Budesonide / Formoterol within 7 days of hospitalization was associated with lower hospital readmission rates for Pulmonary Disease Patients. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.